Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Gac. méd. Méx ; 156(6): 533-536, nov.-dic. 2020. tab
Artigo em Espanhol | LILACS | ID: biblio-1249963

RESUMO

Resumen La revisión por pares tradicional atraviesa por crecientes cuestionamientos, dado el aumento en el fraude científico detectado y la crisis de replicación que recientemente se ha presentado en la investigación biomédica. Investigadores, instituciones académicas y agencias de financiamiento activamente promueven el análisis del registro científico y se han desarrollado múltiples herramientas para lograrlo. Diferentes revistas biomédicas se fundaron con la revisión por pares pospublicación como característica; existen varias plataformas digitales que hacen posible este proceso. Asimismo, cada vez hay más revistas biomédicas que permiten comentar artículos publicados en sus sitios web, lo cual también es posible en repositorios de preimpresiones. Sumado a esto, las casas editoriales y los investigadores están usando ampliamente las redes sociales para la difusión y discusión de artículos, lo cual a veces culmina en refutaciones y retracciones.


Abstract Traditional peer review is undergoing increasing questioning, given the increase in scientific fraud detected and the replication crisis biomedical research is currently going through. Researchers, academic institutions, and research funding agencies actively promote scientific record analysis, and multiple tools have been developed to achieve this. Different biomedical journals were founded with post-publication peer review as a feature, and there are several digital platforms that make this process possible. In addition, an increasing number biomedical journals allow commenting on articles published on their websites, which is also possible in preprint repositories. Moreover, publishing houses and researchers are largely using social networks for the dissemination and discussion of articles, which sometimes culminates in refutations and retractions.


Assuntos
Humanos , Editoração/normas , Revisão da Pesquisa por Pares/métodos , Controle de Qualidade , Fatores de Tempo , Má Conduta Científica/estatística & dados numéricos
2.
Bol. méd. Hosp. Infant. Méx ; 71(1): 25-35, ene.-feb. 2014. ilus
Artigo em Inglês | LILACS | ID: lil-728505

RESUMO

Background: Lymphomas are B and/or T cell clonal neoplasms in various states of differentiation, characteristically compromising lymph nodes. They are constituted by B and T lymphocytes that reach the node by chemokine-mediated recruitment including CXCL13. Hypoxia-inducible transcription factor (HIF-1α) plays a role in cellular adaptation to oxygen concentration changes. It also regulates expression of chemokines such as CXCL12, CCL20, and CCL5 as well as some of their receptors such as CCR7 and CXCR4. Methods: We performed in silico analysis of the CXCL13 promoter, pharmacologic modulation of HIF-1α activity and, using reporter plasmids, site-directed mutation and DNA-protein interaction analysis we analyzed the relation between HIF-1α activity and CXCL13 expression. Moreover, we did tissue microarray and immunohistochemistry to see the expression of HIF-1α and CXCL13. Results: This study detected three possible HIF-1α binding sites suggesting that this chemokine may be regulated by the CXCL13 transcription factor. We showed that CXCL13 expression is directly dependent, whereby an increase in HIF-1α activity increases CXCL13 expression and decreased HIF-1α activity in turn decreases CXCL13 expression. We proved that HIF-1α transcriptionally regulates the expression of CXCL13 in a direct manner. We established that HIF-1α and CXCL13 are greatly overexpressed in the most aggressive pediatric lymphomas. Conclusions: For the first time, this study showed that HIF-1α directly regulates transcriptional CXCL13 and that both proteins are overexpressed in the most aggressive forms of pediatric lymphoma. This suggests that they may play a significant role in the pathogenesis of pediatric non-Hodgkin's lymphoma.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA